Events (34)

• November 21, 1996: Merck Official Concerned that Study Would Show that Vioxx Causes Heart Problems 1996-11-21
• November 23, 1998: Merck Submits Application for Vioxx Approval to FDA 1998-11-23
• November 18, 1999: VIGOR Study Indicates Risk of Heart Problems among Patients Taking Vioxx 1999-11-18
• December 22, 1999: VIGOR Study Provides Clearer Evidence of Heart Problems Among Users of the Drug Vioxx 1999-12-22
• February 15, 2000: Head of Vioxx Study to be Paid $60,000 to sit on Merck Advisory Board 2000-02-15
• March 9, 2000: Merck Scientist Notes that Anticipated Heart Problems Among Vioxx Users Are a ‘Shame’ 2000-03-09
• March 27, 2000: VIGOR Study Results Announced 2000-03-27
• March 30, 2000: Merck Scientist Suggests Combining Vioxx with an Anti-Clotting Agent 2000-03-30
• April 28, 2000: Merck Advises Sales Reps on How to Deal with Questions about VIGOR Study 2000-04-28
• May 18, 2000: Merck Submits Results of Vioxx Study to New England Journal of Medicine 2000-05-18
• October 13, 2000: Merck Informs FDA of Last Three Deaths in Vioxx Clinical Study 2000-10-13
• February 9, 2001: Merck Warns Sales Reps to Avoid Questions about Vioxx and Cardiovascular Safety 2001-02-09
• May 22, 2001: Merck Issues Deceptive Press Release Asserting ‘Cardiovascular Safety Profile of Vioxx’ 2001-05-22
• May 22, 2001: Merck Instructs Sales Reps on How to Handle Physicians Asking about Concerns Raised in New York Times Article 2001-05-22
• May 22, 2001: New York Times Reports on Results of VIGOR Study 2001-05-22
• September 17, 2001: FDA Accuses Merck of Deceptive Marketing Campaign for its Drug Vioxx 2001-09-17
• April 11, 2002: Merck Adds a Warning about Cardiovascular Risk to Vioxx Label 2002-04-11
• August 25, 2004: Study by FDA Scientist Suggests 27,000 Americans Have Died from Taking Vioxx 2004-08-25
• After November 7, 2006: Drug Companies Hire Lobbyists with Ties to Democrats 2006-11-07
• September 12, 2009 and After: Obama, Senate Democrat Work with Pharmaceutical Organization to Remove Key Medicare Provision from Health Care Reform 2009-09-12
• Mid-November 2006: Drug Company Executives Meet and Plan Strategy to Oppose Price Caps
• 2001: Merck Develops Game ‘Dodge Ball Vioxx’ to Train Sales Force on How to Deal with Doctors’ Concerns
• October 3 or 4, 1999: VIGOR Study Indicates Minimal Stomach Problems; No Evidence of Heart Problems
• 1998: Scientists Ties COX-2 Inhibitors to Heart Problems
• Early February 2000: Merck Agrees to Analyze Vioxx Deaths; But Insists on a Cut-Off Date for the Data
• January 2000: Merck Rejects Request to Begin Immediate Analysis of Deaths from Vioxx Drug
• March 2001: Merck Instructs Sales Representatives Not to Discuss Studies Critical of Merck Products
• January 2002: Merck Uses Detailed Information on Doctor’s Prescribing Habits to Market Company’s Drugs
• January 2002: Merck Training Manual for Sales Reps Recommends Comparing Themselves to People like Martin Luther King
• 1998: Merck Study Suggests Increased Risk of Heart Problems among People Taking Vioxx
• June 2005-July 2005: Survey Suggests that Drug Industry Sales Reps Know Little about the Products they Sell
• March 2000: VIGOR Study Ends; 20 Deaths among Patients Taking Vioxx
• January 1999: Merck Launches VIGOR Clinical Trial of Vioxx
• 2001: Merck Files Patent Application for a New Version of Vioxx that Would Not Harm Heart